Paul K. Paik, MD, reviews the importance of biomarker testing and best practices in testing in patients with non-small cell lung cancer.
Advances in Biomarker-Driven Therapy for Advanced NSCLC
An expert in non-small cell lung cancer describes targetable gene alterations and how these impact treatment selection.
Paul K. Paik, MD, discusses currently available targeted therapies for patients with NSCLC.
A key opinion leader thoracic oncology reviews the clinical significance of MET exon 14 skipping in NSCLC as well as recent advances in MET-directed therapy.
An expert in non-small cell lung cancer discusses the key efficacy and safety findings from the VISION trial of tepotinib in patients with NSCLC and MET exon 14 skipping alterations.
Paul K. Paik, MD, discusses how the results of the VISION trial and the recent FDA approval of tepotinib will impact clinical practice.
Paul K. Paik, MD, considers the future of MET-directed therapies in non-small cell lung cancer.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FDA tentatively approves first generic lenacapavir for HIV prevention in lower-income countries
2
New pulmonary fibrosis drugs put guidelines in focus, Prusi says | AMCP Nexus 2026
3
Fewer than half of newly diagnosed children with type 1 diabetes get autoantibody testing
4
Targeted therapies for atopic dermatitis reduce hospitalizations and ER visits, but cost is a different story
5